Cagrilintide + Semiglutide (Blend) (10 (5/5)ml)
$99.00
A precision research blend combining cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, for laboratory investigation of complementary metabolic signaling pathways.
Buy 1
SAVE 0%
Buy 3
SAVE 20%
Buy 5
SAVE 33%
Buy 7+
SAVE 50%
Description
This research blend combines two pharmacologically distinct compounds under active scientific investigation in metabolic research: cagrilintide, a long-acting amylin analog that activates amylin receptors (AMY1–AMY3) associated with satiety and energy regulation; and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist studied extensively for its role in glucose metabolism and appetite signaling.
Together, these compounds represent complementary targets within the neurohormonal regulation of metabolism. Their combined investigation in laboratory settings reflects growing scientific interest in multimodal metabolic signaling research, particularly the interplay between amylin and GLP-1 receptor pathways. Both compounds have been the subject of significant clinical research, providing a well-characterized scientific foundation for laboratory investigation.
Supplied as a precision-blended Research Use Only (RUO) material, analytically verified for the identity and purity of both components, with batch-specific Certificate of Analysis documentation. Note: semaglutide is an FDA-approved pharmaceutical in clinical contexts. This product is supplied solely as an RUO research material.
